Vivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERNGet Free Report) major shareholder Vivo Opportunity, Llc sold 138,066 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $6.20, for a total transaction of $856,009.20. Following the completion of the transaction, the insider now directly owns 268,573 shares of the company’s stock, valued at $1,665,152.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Vivo Opportunity, Llc also recently made the following trade(s):

  • On Monday, April 1st, Vivo Opportunity, Llc sold 181,117 shares of Terns Pharmaceuticals stock. The shares were sold at an average price of $6.99, for a total transaction of $1,266,007.83.

Terns Pharmaceuticals Stock Performance

TERN opened at $6.00 on Thursday. Terns Pharmaceuticals, Inc. has a fifty-two week low of $3.26 and a fifty-two week high of $14.04. The company has a market capitalization of $387.90 million, a P/E ratio of -4.72 and a beta of -0.63. The stock has a fifty day moving average of $6.75 and a 200-day moving average of $5.87.

Terns Pharmaceuticals (NASDAQ:TERNGet Free Report) last posted its earnings results on Thursday, March 14th. The company reported ($0.29) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.29). On average, equities research analysts predict that Terns Pharmaceuticals, Inc. will post -1.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

TERN has been the subject of several analyst reports. BMO Capital Markets raised their target price on shares of Terns Pharmaceuticals from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, March 15th. JMP Securities cut their price target on Terns Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Monday, March 18th. HC Wainwright reaffirmed a “neutral” rating and set a $5.50 price target on shares of Terns Pharmaceuticals in a report on Friday, March 15th. Finally, UBS Group cut their price target on Terns Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 27th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.94.

View Our Latest Research Report on TERN

Institutional Investors Weigh In On Terns Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Tucker Asset Management LLC acquired a new position in Terns Pharmaceuticals in the second quarter valued at about $25,000. Ameritas Investment Partners Inc. acquired a new position in Terns Pharmaceuticals in the second quarter valued at about $31,000. China Universal Asset Management Co. Ltd. raised its stake in Terns Pharmaceuticals by 358.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,147 shares of the company’s stock valued at $46,000 after purchasing an additional 5,587 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Terns Pharmaceuticals in the first quarter valued at about $46,000. Finally, AJOVista LLC acquired a new position in Terns Pharmaceuticals in the fourth quarter valued at about $58,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

About Terns Pharmaceuticals

(Get Free Report)

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Featured Stories

Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.